[Previous Months][Date Index][Thread Index][Join - Register][Login]
  [Message Prev][Message Next][Thread Prev][Thread Next]

Re: [IP] amylien study--More INFO

>From the website: http://www.amylin.com

Amylin Pharmaceuticals, Inc. is engaged in the discovery, development and 
commercialization of potential drug candidates for the treatment of metabolic 
B  <A HREF="http://www.amylin.com/website/Pipeline/Symlin.htm">SYMLINb" (pramlintide acetate)</A> 
    SYMLIN is a synthetic version of human amylin, a hormone secreted with 
insulin by the beta cells in the pancreas. In clinical studies, SYMLIN has 
exhibited actions that complement those of insulin in maintaining metabolic 
control. Phase 3 SYMLIN studies demonstrated statistically significant 
improvements in blood glucose control without weight gain in people with type 
1 or type 2 diabetes using insulin. These reductions in blood glucose were 
achieved with no increase in severe hypoglycemic event rates compared to the 
control group.B  Amylin submitted a New Drug Application (NDA) to the US Food 
and Drug Administration in December 2000 and received an approvable letter in 
October 2001 subject to additional clinical work.B  Marketing Authorization 
Applications for SYMLIN were submitted in Europe in May 2001 and have since 
been accepted for filing by the EMEA and Swiss Regulatory Authorities   

for HELP or to subscribe/unsubscribe, contact: